Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests

Table 2 Early stage breast cancer: economic costs of inaccurate HER2 immunohistochemical test results. Based on FN and FP test results (Nordic Immunohistochemistry Quality Control Group data), US treatment costs, US patient numbers and US productivity data; weighted according to the estimated prevalence of immunohistochemistry scores

	Early stage breast cancer
Cost, US $	Approved IVD	Laboratory-developed IVD	Difference
Direct cost/patient	364	1394	1030
Total direct costs^a	14 447 666	55 377 720	40 930 054
Cost of lost productivity/patient^b	83	190	107
Total cost of lost productivity^c	3 301 263	7 546 231	4 244 968

IVD in vitro diagnostic
^aCosts corrected for the prevalence of IHC 2+ tumours [19]. ^bProductivity loss per year per patient undergoing a HER2 test. ^cCost for the annual number of new patients undergoing a HER2 test and receiving systemic treatment in the USA

ISSN: 1472-6963